APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In vitro and in vivo evaluation revealed that apoA-I and CIGB-258, in their lipid-free form, display synergistic antioxidant and anti-inflammatory effects against CML-induced acute inflammation.